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 Introduction  
 Sixty years ago, Leo Kanner first labeled brain develop-
ment disorder as autism spectrum disorder (ASD), and 
since then its cause and treatment have been poorly un-
derstood  [1, 2] . However, autism is no longer defined by 
etiology or pathology but by the presence of a pattern of 
behavioral characteristics that accompany a particular 
developmental course, with evidence of developmental 
delay within the first 3 years of life  [1–4] . 
 Hedgehog proteins are involved in many essential de-
velopmental processes in vertebrates and invertebrates 
 [5] . The protein produced from the desert hedgehog 
 (Dhh) gene is believed to be involved in male sexual de-
velopment (spermatogenesis) and in the formation of the 
perineurium, the protective membrane around each bun-
dle of fibers within a nerve  [6] . This process involves the 
recruitment of neurons, glia (Schwann cells), blood ves-
sels, fibroblasts, and extracellular matrix to build a struc-
ture that allows the ready and uninterrupted conduction 
of impulses along axons in an environment that is subject 
to ongoing movement and continuous mechanical stress.
 We have recently reported that the serum levels of the 
Sonic hedgehog (Shh) protein and brain-derived neuro-
trophic factor (BDNF) might be linked to oxidative stress 
in ASD  [4, 7] . The Dhh and Shh proteins belong to the 
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 Abstract 
 Objective: To investigate the role of desert hedgehog  (Dhh) 
in a neurodevelopmental disorder known as autism.  Sub-
jects and Methods: This study was conducted at the Autism 
Research and Treatment Center, King Khalid University Hos-
pital, Riyadh, Kingdom of Saudi Arabia from October 2011 to 
May 2012. The serum levels of the Dhh protein in 57 patients 
recently diagnosed with autism and 37 age-matched healthy 
children were measured using ELISA. The Childhood Autism 
Rating Scale (CARS) was used for the assessment of autistic 
severity.  Results: The mean serum level of  Dhh in patients 
with autism (1.38 ± 0.50 ng/ml) was significantly lower (p = 
0.0003) than that of normal controls (1.73 ± 0.37 ng/ml). 
There was no significant relationship between the serum 
level of Dhh and the CARS score (p = 0.28), age (p = 0.51) or 
gender (p = 0.76).  Conclusions: The  Dhh  serum level of pa-
tients with autism was lower than that of controls, probably 
indicating that the serum level of  Dhh  might be implicated 
in the physiology of autism. However, this finding should be 
treated with caution until further investigations are per-
formed with larger populations.  © 2013 S. Karger AG, Basel 
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Hedgehog family. However, the role of activating  Dhh 
signaling in these diseases is still elusive. The excess of 
neurotrophins and neuropeptides in sera of newborn in-
fants has a predictive value in determining the children 
who will later have a disruption of intellectual and or so-
cial development. Biological markers have to be found 
that may allow earlier detection of autism. Thus the aim 
of the current study was to explore a possible role of the 
Dhh protein in children with autism.
 Subjects and Methods 
 Participants 
 Fifty-seven children (53 boys and 4 girls) with ASD were re-
cruited for this study with a mean age of 6 ± 1.72 years (range: 3–11 
years), and 37 (33 males and 4 females) age- and sex-matched 
healthy children (mean age: 7.04 ± 1.74 years; range: 3–11 years) 
served as controls. The diagnosis of ASD was made by a child neu-
ropsychiatrist (S.B.) and a pediatrician (D.M.) based on the criteria 
of ASD as defined in the DSM-IV  [2] on the day of the screening 
test. The Childhood Autism Rating Scale (CARS) was completed 
as a further measurement of the severity of ASD  [8] . The CARS 
rates the child on a scale from 1 to 4 in each of 15 areas (relating to 
people; emotional response; imitation; body use; object use; listen-
ing response; fear or nervousness; verbal communication; nonver-
bal communication; activity level; level and reliability of intellec-
tual response; adaptation to change; visual response; taste, smell 
and touch response and general impressions). Written consent 
was obtained from the parents of each subject, according to the 
guidelines of the Ethics Committee of King Khalid Hospital, King 
Saud University, Riyadh, Saudi Arabia. All procedures that fol-
lowed were in accordance with the Helsinki Declaration. This 
study was conducted at the Autism Research and Treatment Cen-
ter, King Khalid University Hospital, Riyadh, Kingdom of Saudi 
Arabia from October 2011 to May 2012.
 Blood Samples 
 After an overnight fast, a 3-ml blood sample was collected from 
each subject (autism and control) in plain test tubes. Blood samples 
were allowed to clot, and then centrifuged at 3,000 rpm to collect 
serum samples, which were stored frozen in a freezer at  − 80   °   C 
until the time of analytical assays. A detailed description of the 
procedure has been described previously  [4, 9] . All samples were 
assayed in duplicate and in a double-blind manner. The assay re-
producibility generally ranged from 5 to 10% error.
 Dhh Assay 
 The serum level of Dhh was measured using a commercially 
available sandwich enzyme immunoassay (ELISA) kit from CUS-
ABIO BIOTECH Co. Ltd. (Wuhan, China).
 Statistical Analysis 
 The data are presented as means ± standard deviation. Statisti-
cal differences were ascertained by using Student’s t test with sig-
nificance set at a p value of 0.05 or lower. The relationship between 
 Dhh levels and the CARS among patients with autism was evalu-
ated by computing Pearson’s correlation coefficients.
 Results 
 The demographic data of the autistic and control sub-
jects are given in  table 1 . There were no significant differ-
ences in the male/female ratio or age between the two 
study groups. The serum  Dhh levels of the patients (1.38 
± 0.50 ng/ml) were significantly lower than those of nor-
mal control subjects (1.73 ± 0.37 ng/ml; p = 0.0003;  fig. 1 ; 
 table 1 ). The scores on the CARS range from 15 to 60, 
whereas individuals with scores lower than 30 are catego-
rized as nonautistic. A CARS score between 30 and 36.5 
(n = 31) indicates mild to moderate autism and scores 
ranging from 37 to 60 indicate severe autism (n = 26). The 
mean serum level of patients with mild to moderate au-
tism (n = 31 and CARS score <36.5) was 1.36 ± 0.48 mg/l 
while that of those with severe autism (n = 26 and CARS 
score >36.5) was 1.39 ± 0.6 ng/ml. The difference was not 
statistically significant (p = 0.26).
 Further, the serum  Dhh levels of autistic subjects had 
no significant correlation with their age (p = 0.51).
 Discussion 
 The current study is the first to demonstrate a signifi-
cant decrease in  Dhh serum levels in subjects with autism 
as compared to normally developing controls. Although 
caution should be exercised in the interpretation of our 
data, they suggest a potential role for  Dhh factors in this 
neurodevelopmental disorder. 
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 Fig. 1. Serum levels of the Dhh protein in control and autistic chil-
dren. Highly statistically significant Dhh serum level in autism 
compared to control (p = 0.003). 
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 Thus, while there is clearly a variety of  Dhh in indi-
viduals with autism, these two facts imply two things. 
First, the presence of these Dhh proteins may be a second-
ary marker of the disease rather than directly pathogenic. 
Second, individual children with a similar clinical pheno-
type have very different immune responses to the protein 
we studied. The results demonstrated no significant cor-
relation between the severity of autism and serum  Dhh 
levels in autistic subjects. 
 The serum levels of the Shh protein and BDNF might 
be linked to oxidative stress in ASD as has recently been 
reported  [4, 7] . BDNF is a small protein found throughout 
the CNS and peripheral blood. BDNF is the most widely 
distributed neurotrophin in the CNS. Within the nervous 
system, the Shh protein is associated with the develop-
ment and patterning of the CNS  [10, 11] . We have shown 
a reduction in BDNF in ASD children in a previous report 
 [4] . BDNF belongs to the neurotrophin family that may 
affect neuronal survival and differentiation.  Dhh is a mor-
phogen important for the nerve development  [6, 12] . Dur-
ing the inflammatory episode, molecules affecting the 
nerve functions, such as ion channels, and with long-term 
effects involving inflammatory tissue damage are secreted 
 [13] . Since  Dhh signaling is an important factor in build-
ing the barriers that protect nerves against mechanical as-
sault and inflammation-related damage, the significantly 
lower  Dhh serum levels found in autistic subjects as com-
pared to controls could be part of the pathophysiology in 
autism, and  Dhh may exert a neuroprotective effect. 
 The chief caveats of our report are the small sample 
size and its cross-sectional design. We thus observed as-
sociations, not prediction or causation. These caveats 
notwithstanding, we have demonstrated an alteration of 
the  Dhh levels in patients with autism characterized by a 
clear imbalance of important  Dhh factors. 
 Conclusion 
 The  Dhh  serum levels of patients with autism were 
lower than those of controls, probably indicating that the 
serum level of  Dhh  might be implicated in the physiology 
of autism . However, these data should be treated with 
caution until further investigations are performed, with 
larger samples, to determine whether the lower serum 
levels of  Dhh are a mere consequence of autism or have a 
pathogenic role in the disease.
 Acknowledgements 
 Work on this study was supported by grants from the King Ab-
dulaziz City for Science and Technology, the National Plane of 
Science and Technology Health Research program, and the Dean-
ship of Scientific Research grant (RGP-VPP-216) from King Saud 
University, Saudi Arabia. 
Table 1.  Serum levels of Dhh in autistic children and their relation to the severity of autism
Age, years Gender Dhh, ng/ml p value CARS
score
Patients with autism (n = 57) 6 ± 1.72 53 male, 4 female 1.38 ± 0.50
Patients with mild to moderate autism (n = 36) 6 ± 1.38 33 male, 3 female 1.36 ± 0.49 <0.004a <36.5
Patients with severe autism (n = 21) 6 ± 2.06 20 male, 1 female 1.39 ± 0.61 <0.05b, <0.64c >36.5
Healthy children (n = 37) 7.04 ± 1.74 33 male, 4 female 1.73 ± 0.37 <0.0003d
 Figures for age and Dhh are given as means ± SD.
a Comparing control subjects with mild to moderate autistic children. b Comparing control subjects with severe autistic children.
c Comparing mild to moderate with severe autistic children. d Comparing control subjects with autistic children.
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